These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10807457)

  • 1. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.
    Heeschen C; Hamm CW; Bruemmer J; Simoons ML
    J Am Coll Cardiol; 2000 May; 35(6):1535-42. PubMed ID: 10807457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
    Lenderink T; Boersma E; Heeschen C; Vahanian A; de Boer MJ; Umans V; van den Brand MJ; Hamm CW; Simoons ML;
    Eur Heart J; 2003 Jan; 24(1):77-85. PubMed ID: 12559939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic findings in patients with refractory unstable angina according to troponin T status.
    Heeschen C; van Den Brand MJ; Hamm CW; Simoons ML
    Circulation; 1999 Oct; 100(14):1509-14. PubMed ID: 10510053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris.
    Rebuzzi AG; Quaranta G; Liuzzo G; Caligiuri G; Lanza GA; Gallimore JR; Grillo RL; Cianflone D; Biasucci LM; Maseri A
    Am J Cardiol; 1998 Sep; 82(6):715-9. PubMed ID: 9761079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
    Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of C-reactive protein and troponin T level in patients with unstable angina pectoris].
    Tanaka H; Tsurumi Y; Kasanuki H
    J Cardiol; 2006 Apr; 47(4):173-9. PubMed ID: 16637251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes.
    Lenderink T; Heeschen C; Fichtlscherer S; Dimmeler S; Hamm CW; Zeiher AM; Simoons ML; Boersma E;
    J Am Coll Cardiol; 2006 Jan; 47(2):307-11. PubMed ID: 16412852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
    Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
    Morrow DA; Rifai N; Antman EM; Weiner DL; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 1998 Jun; 31(7):1460-5. PubMed ID: 9626820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
    Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
    Lindahl B; Toss H; Siegbahn A; Venge P; Wallentin L
    N Engl J Med; 2000 Oct; 343(16):1139-47. PubMed ID: 11036119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
    Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    van den Brand MJ; Simoons ML; de Boer MJ; van Miltenburg A; van der Wieken LR; de Feyter PJ
    Eur Heart J; 1995 Nov; 16 Suppl L():36-42. PubMed ID: 8869017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stratification of cardiac risk in unstable angina: value of troponin measurements].
    Chérif A; Messaoudi H; Mourali S; Ezzar T; Boussaada R; Mechmèche R
    Tunis Med; 2002 Oct; 80(10):581-3. PubMed ID: 12632750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation.
    Alcock RF; Roy P; Adorini K; Lau GT; Kritharides L; Lowe HC; Brieger DB; Freedman SB
    Int J Cardiol; 2010 Apr; 140(1):66-72. PubMed ID: 19131135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
    Ottervanger JP; Armstrong P; Barnathan ES; Boersma E; Cooper JS; Ohman EM; James S; Topol E; Wallentin L; Simoons ML;
    Circulation; 2003 Jan; 107(3):437-42. PubMed ID: 12551868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention.
    Mueller C; Neumann FJ; Perruchoud AP; Zeller T; Buettner HJ
    Am J Med; 2004 Dec; 117(12):897-902. PubMed ID: 15629727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.